The SLLIP trial retrospectively assessed the BRAF mutational spectrum of 185 newly diagnosed advanced lung adenocarcinoma patients and indicated that the class of BRAF mutations should be taken into account during therapeutic decisions, as this was confirmed through cell viability experiments [233]. The gene discussed is BRAF; the disease is lung adenocarcinoma.